SCHEMBL102273

SCHEMBL102273

Cc1nc(Br)sc1C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3148508 0.75
SCHEMBL1922601 0.75
SCHEMBL3906570 0.73
SCHEMBL77218 0.71
SCHEMBL10022977 0.71 NOS1 (0.52)
SCHEMBL27982173 0.71
SCHEMBL22865268 0.71
SCHEMBL15304320 0.71
SCHEMBL11489805 0.71
Hydrochloric Acid SCHEMBL27810722 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1753683-B Ophthalmic formulation for the prevention and treatment of ocular conditions CHAKSHU RES INC 2010-05-26 CN claimed
EP-1751113-B1 UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS BRISTOL MYERS SQUIBB CO (US) 2010-03-10 EP claimed
CN-1753683-A Ophthalmic formulation for the prevention and treatment of ocular conditions CHAKSHU RES INC (US) 2006-03-29 CN claimed
US-20040019219-A1 N-alkylated thiazolium salts and process for their preparation LANXESS DEUTSCHLAND GMBH (DE) 2004-01-29 US claimed
EP-1371651-A2 N-alkylated Thiazoliumsalts and processes for their preparation BAYER AG (DE) 2003-12-17 EP claimed
EP-4448492-B1 COMPOSITIONS AND METHODS OF MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER REGLAGENE INC (US) 2026-03-04 EP disclosed
EP-4658656-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES Beone Medicines I GmbH (CH) 2025-12-10 EP disclosed
US-20250346597-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES BEONE MEDICINES I GMBH (CH) 2025-11-13 US disclosed
EP-4630025-A1 EXTRACT OF ALGAE OF THE GENUS ULVA FOR THE TREATMENT OF DISORDERS CAUSED BY A METABOLIC SYNDROME UNIVERSITE DE BORDEAUX (FR) 2025-10-15 EP disclosed
US-12404242-B2 Compositions and methods for making and using small molecules in the treatment of cancer REGLAGENE, INC. (US) 2025-09-02 US disclosed
EP-4269400-B1 YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS MOLECURE SA (PL) 2025-07-09 EP disclosed
EP-4543544-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF Biogen MA Inc. (US) 2025-04-30 EP disclosed
US-20020156287-A1 Condensation reagents and a process for their preparation LANXESS DEUTSCHLAND GMBH (DE) 2002-10-24 US disclosed
EP-1216997-A2 2-bromo/chloro-thiazolium salts and their use as condensation agents BAYER AG (DE) 2002-06-26 EP disclosed
EP-1214303-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF Merck & Co., Inc. (US) 2002-06-19 EP disclosed
WO-2001016121-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF MERCK & CO., INC. (US) 2001-03-08 WO disclosed
US-5877156-A Thrombin inhibitors AKZO NOBEL, N.V. (NL) 1999-03-02 US disclosed
EP-0884325-A1 Thrombin inhibitors containing a peptidyl heterocycle Akzo Nobel N.V. (NL) 1998-12-16 EP disclosed
US-5030727-A Reacting an anthronilide derivative with a thiazole derivative or a fluorozuinazolone with a neucleophile BASF AKTIENGESELLSCHAFT (DE) 1991-07-09 US disclosed
EP-0263523-A2 Process for the preparation of thiazolo [2,3-b] quinazolones BASF Aktiengesellschaft (DE) 1988-04-13 EP disclosed